 |
|
The Effects of Pharmacologically Induced Hypogonadism on Mood in Healthy Men
Peter J. Schmidt, MD;
Kate L. Berlin, BA;
Merry A. Danaceau, RN, MSNCS;
Amy Neeren, BA;
Nazli A. Haq, MA;
Catherine A. Roca, MD;
David R. Rubinow, MD
Arch Gen Psychiatry. 2004;61:997-1004.
Background The effects of declining androgen secretion on mood regulation and the potential psychotropic efficacy of androgen replacement in men are largely undetermined.
Objective To examine the effects on mood of the acute suppression of testosterone secretion.
Design A double-blind, placebo-controlled, crossover (self-as-own-control) study.
Setting An ambulatory care clinic in a research hospital.
Participants Thirty-one healthy adult men with no history of psychiatric illness or substance or anabolic steroid abuse.
Interventions Men received depot leuprolide acetate (Lupron, 7.5 mg intramuscularly) every 4 weeks for 3 months. After the first month of Lupron alone, all men received (in addition to Lupron) testosterone enanthate (200 mg intramuscular) or placebo (sesame oil as color-matched vehicle) every 2 weeks for 1 month each in a crossover design. The order of administration of testosterone and placebo was randomly assigned and counterbalanced.
Main Outcome Measures Mood and behavior rating scores (self-report and rater administered).
Results With the exceptions of hot flushes, libido, and the feeling of being emotionally charged, none of the symptoms measured showed a significant difference across eugonadal, Lupron plus placebo, and Lupron plus testosterone conditions. Despite the absence of a uniform effect of Lupron plus placebo on mood, 3 men experienced clinically relevant mood symptoms during this induced hypogonadal condition. High baseline levels of sexual functioning predicted the greatest decline in sexual function during Lupron plus placebo.
Conclusions These data, the first to describe the effects on mood of induced hypogonadism in healthy young men, suggest that short-term hypogonadism is sufficient to precipitate depressive symptoms in only a small minority of younger men. The predictors of this susceptibility remain to be determined.
Author Affiliations: Behavioral Endocrinology Branch, National Institute of Mental Health, National Institutes of Health (Drs Schmidt, Roca, and Rubinow and Mss Berlin, Neeren, and Haq), and the Department of Nursing, National Institutes of Health Clinical Center (Ms Danaceau), Bethesda, Md.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati
What's this?
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
Potential Side Effects of Androgen Deprivation Treatment in Sex Offenders
Giltay and Gooren
J Am Acad Psychiatry Law 2009;37:53-58.
ABSTRACT
| FULL TEXT
Selective contributions of the medial preoptic nucleus to testosterone-dependant regulation of the paraventricular nucleus of the hypothalamus and the HPA axis
Williamson and Viau
Am. J. Physiol. Regul. Integr. Comp. Physiol. 2008;295:R1020-R1030.
ABSTRACT
| FULL TEXT
State of the Art Reviews: Male Menopause: Fact or Fiction?
Wald et al.
AMERICAN JOURNAL OF LIFESTYLE MEDICINE 2008;2:132-141.
ABSTRACT
The Rationale for Banning Human Chorionic Gonadotropin and Estrogen Blockers in Sport
Handelsman
J. Clin. Endocrinol. Metab. 2006;91:1646-1653.
ABSTRACT
| FULL TEXT
Monoamines and neurosteroids in sexual function during induced hypogonadism in healthy men.
Bloch et al.
Arch Gen Psychiatry 2006;63:450-456.
ABSTRACT
| FULL TEXT
Sex-Related Differences in Stimulated Hypothalamic-Pituitary-Adrenal Axis during Induced Gonadal Suppression
Putnam et al.
J. Clin. Endocrinol. Metab. 2005;90:4224-4231.
ABSTRACT
| FULL TEXT
|
